<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081832</url>
  </required_header>
  <id_info>
    <org_study_id>16/8407</org_study_id>
    <secondary_id>2016-A01348-43</secondary_id>
    <nct_id>NCT03081832</nct_id>
  </id_info>
  <brief_title>Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.</brief_title>
  <acronym>OT2SUITE</acronym>
  <official_title>Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Syndrome Infants (OT2SUITE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect data on tolerance and effects of early treatment
      with oxytocin in children with Prader Willi Syndrome aged from 3 to 4 years and to compare
      these infants with not treated age-matched infants with Prader Willi Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In accordance with recommendations of regulatory authorities, we want to collect long term
      data of patients treated with oxytocin before the age of 6 months. Moreover clinical
      observations of these infants support long term effects on communication skills, global
      development and behaviour.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of communication skills.</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessed by Vineland-II scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adaptative behavior composite and 3 domains : &quot;Daily living skills&quot;, &quot;Socialization&quot;, &quot;Motor skills&quot;.</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessed by Vineland-II scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of behavioral troubles.</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessed by Child Behaviour Check List questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of global development.</measure>
    <time_frame>Day 2 and 3</time_frame>
    <description>Assessed by Bayley Scales of Infant and Toddler Development.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of orality and eating behaviour.</measure>
    <time_frame>Day 2</time_frame>
    <description>Assessed by:
A questionnaire on eating behavior.
An oral evaluation, which combines a clinical examination carried out by the reference center physician, and the assessment of eating behavior during the meal.
The fluoroscopy of swallowing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of brain activity.</measure>
    <time_frame>Day 3</time_frame>
    <description>Assessed by a morphological Magnetic resonance imaging, a resting functional Magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of plasma levels of ghrelin and other peptides involved in feeding behaviour or energy metabolism.</measure>
    <time_frame>Day 1</time_frame>
    <description>Circulating levels of acylated and non-acylated ghrelin and some peptides and neuropeptides involved in appetite regulation (leptin, cortisol, insulin, Glucagon like peptide-1, pancreatic polypeptide, orexin A, alpha-melanocyte stimulating hormone...).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Not treated.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants with Prader Willi Syndrome (genetic diagnosis confirmed)

          -  For treated group : infant included in the ancient study

          -  For not treated group: infant never treated with oxytocin

        Exclusion Criteria:

          -  Subject involved in another search including an exclusion period still in progress at
             the time of inclusion.

          -  Impossibility to give parents or legal guardian informed information

          -  No coverage by a Social Security scheme

          -  Refusal of parents or legal representative to sign consent.

        If a patient has a contraindication to Magnetic resonance imaging, it may be included in
        the study but Magnetic resonance imaging will not be performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maïthé Tauber, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de référence du syndrome de Prader-Willi- CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maïthé Tauber, Pr</last_name>
    <phone>5 34 55 85 51</phone>
    <phone_ext>33</phone_ext>
    <email>tauber.mt@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de référence du syndrome de Prader-Willi Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maïthé Tauber, Pr</last_name>
      <phone>5 34 55 85 51</phone>
      <phone_ext>33</phone_ext>
      <email>tauber.mt@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Maïthé Tauber, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenaëlle Diene, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Çabal-Berthoumieu, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale Fichaux-Bourin, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Amico JA, Vollmer RR, Cai HM, Miedlar JA, Rinaman L. Enhanced initial and sustained intake of sucrose solution in mice with an oxytocin gene deletion. Am J Physiol Regul Integr Comp Physiol. 2005 Dec;289(6):R1798-806. Epub 2005 Sep 8.</citation>
    <PMID>16150836</PMID>
  </reference>
  <reference>
    <citation>Arletti R, Benelli A, Bertolini A. Oxytocin inhibits food and fluid intake in rats. Physiol Behav. 1990 Dec;48(6):825-30.</citation>
    <PMID>2087513</PMID>
  </reference>
  <reference>
    <citation>Billings LB, Spero JA, Vollmer RR, Amico JA. Oxytocin null mice ingest enhanced amounts of sweet solutions during light and dark cycles and during repeated shaker stress. Behav Brain Res. 2006 Jul 15;171(1):134-41. Epub 2006 May 4.</citation>
    <PMID>16677726</PMID>
  </reference>
  <reference>
    <citation>Bittel DC, Kibiryeva N, Sell SM, Strong TV, Butler MG. Whole genome microarray analysis of gene expression in Prader-Willi syndrome. Am J Med Genet A. 2007 Mar 1;143A(5):430-42.</citation>
    <PMID>17236194</PMID>
  </reference>
  <reference>
    <citation>Dykens EM, Lee E, Roof E. Prader-Willi syndrome and autism spectrum disorders: an evolving story. J Neurodev Disord. 2011 Sep;3(3):225-37. doi: 10.1007/s11689-011-9092-5. Epub 2011 Aug 20.</citation>
    <PMID>21858456</PMID>
  </reference>
  <reference>
    <citation>Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring). 2007 Jul;15(7):1816-26.</citation>
    <PMID>17636101</PMID>
  </reference>
  <reference>
    <citation>Dykens EM, Roof E, Hunt-Hawkins H. Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. J Child Psychol Psychiatry. 2017 Jan;58(1):64-74. doi: 10.1111/jcpp.12601. Epub 2016 Aug 2.</citation>
    <PMID>27481444</PMID>
  </reference>
  <reference>
    <citation>Goldstone AP, Holland AJ, Butler JV, Whittington JE. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes (Lond). 2012 Dec;36(12):1564-70. doi: 10.1038/ijo.2011.274. Epub 2012 Jan 24.</citation>
    <PMID>22270375</PMID>
  </reference>
  <reference>
    <citation>Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010 Apr 1;67(7):692-4. doi: 10.1016/j.biopsych.2009.09.020. Epub 2009 Nov 7.</citation>
    <PMID>19897177</PMID>
  </reference>
  <reference>
    <citation>Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012 Apr;37(4):509-18. doi: 10.1016/j.psyneuen.2011.07.020. Epub 2011 Aug 20.</citation>
    <PMID>21862226</PMID>
  </reference>
  <reference>
    <citation>Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6.</citation>
    <PMID>15931222</PMID>
  </reference>
  <reference>
    <citation>Lischke A, Gamer M, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC, Domes G. Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology. 2012 Sep;37(9):1431-8. doi: 10.1016/j.psyneuen.2012.01.011. Epub 2012 Feb 23.</citation>
    <PMID>22365820</PMID>
  </reference>
  <reference>
    <citation>McDonald NA, Kuzmiski JB, Naderi N, Schwab Y, Pittman QJ. Endogenous modulators of synaptic transmission: cannabinoid regulation in the supraoptic nucleus. Prog Brain Res. 2008;170:129-36. doi: 10.1016/S0079-6123(08)00412-3. Review.</citation>
    <PMID>18655878</PMID>
  </reference>
  <reference>
    <citation>Meziane H, Schaller F, Bauer S, Villard C, Matarazzo V, Riet F, Guillon G, Lafitte D, Desarmenien MG, Tauber M, Muscatelli F. An Early Postnatal Oxytocin Treatment Prevents Social and Learning Deficits in Adult Mice Deficient for Magel2, a Gene Involved in Prader-Willi Syndrome and Autism. Biol Psychiatry. 2015 Jul 15;78(2):85-94. doi: 10.1016/j.biopsych.2014.11.010. Epub 2014 Nov 20.</citation>
    <PMID>25599930</PMID>
  </reference>
  <reference>
    <citation>Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, Dykens E, Butler MG, Shuster JJ, Driscoll DJ. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011 May;155A(5):1040-9. doi: 10.1002/ajmg.a.33951. Epub 2011 Apr 4.</citation>
    <PMID>21465655</PMID>
  </reference>
  <reference>
    <citation>Salles J, Strelnikov K, Carine M, Denise T, Laurier V, Molinas C, Tauber M, Barone P. Deficits in voice and multisensory processing in patients with Prader-Willi syndrome. Neuropsychologia. 2016 May;85:137-47. doi: 10.1016/j.neuropsychologia.2016.03.015. Epub 2016 Mar 16.</citation>
    <PMID>26994593</PMID>
  </reference>
  <reference>
    <citation>Schaller F, Watrin F, Sturny R, Massacrier A, Szepetowski P, Muscatelli F. A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Hum Mol Genet. 2010 Dec 15;19(24):4895-905. doi: 10.1093/hmg/ddq424. Epub 2010 Sep 28.</citation>
    <PMID>20876615</PMID>
  </reference>
  <reference>
    <citation>Skokauskas N, Sweeny E, Meehan J, Gallagher L. Mental health problems in children with prader-willi syndrome. J Can Acad Child Adolesc Psychiatry. 2012 Aug;21(3):194-203.</citation>
    <PMID>22876265</PMID>
  </reference>
  <reference>
    <citation>Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab. 1995 Feb;80(2):573-9.</citation>
    <PMID>7852523</PMID>
  </reference>
  <reference>
    <citation>van Lieshout CF, de Meyer RE, Curfs LM, Koot HM, Fryns JP. Problem behaviors and personality of children and adolescents with Prader-Willi syndrome. J Pediatr Psychol. 1998 Apr;23(2):111-20.</citation>
    <PMID>9585637</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2017</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prader-Willi</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Communication skills</keyword>
  <keyword>Oral skills</keyword>
  <keyword>Brain activity</keyword>
  <keyword>Hormonal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

